As a break-through technology , cancer immunotherapy represented by stem cell therapy and CAR-T technology draws a lot of attention. Influenced by FDA's approval of Kymriah, many domestic scientists, clinicians and relevant enterprises believe that the spring of cell therapy in China is coming soon!
- Policy and Regulation on Cell Therapy under the New Situation
- Development of Cell Therapy Commercialization in China
- Medical Innovations in Cell Therapy
- Clinical Translation of Cell Therapy
-
- Reconstruction and Normalization of Immune System
- Gene-Editing Modified Cell Therapy
- Tumor Microevironment and Immunotherapy
- Discovery of New Checkpoints in Cancer Immunotherapy
- Cancer Vaccine
- Stem Cell Reprogramming
- Stem Cell-based Functional Repairment of Tissues and Organs
- PDX Animal Models and Immunotherapy
- Acceleration of Clinical Trials of Stem Cells
- Quality Control and Effect Evaluation of Stem Cells
- CAR-T, TCR-T, CAR-NK Cell Therapy
- Clinical Trials of Mesenchymal Stem Cells
- Clinical Trial Design and Evaluation of Stem Cells
- Combination of Immunotherapy and Other Therapies
- Companion Diagnostics and Effect Monitoring of Cancer Immunotherapy
- Automatic CAR-T Cell Preparation
- Liquid Biopsy and Gene Detection of Tumors
- Storation in Low Temperature and Cold Chain Management of Clinical Grade Cells
- Preparation of GMP Grade Plasmids
- Marketing Trends and Commercial Patterns of Cell Therapy Worldwide
- Pricing Strategies and Payment by Medical Insurance
- Process Management and Quality Monitoring of Cell Therapy
A bridge connecting clinicians, researchers, entrepreneurs, investors and fund raising institutions, will be established.
First-class experts will be invited from Chinese Academy of Sciences, CFDA, Ivy Leagues and international joint ventures, to hold discussions of application of cell therapy.
Hot topics, like gene editing, immunotherapy, tumor checkpoints, clinical trials, laws and regulations, will provide you with new thoughts in cell therapy.
Clinicians from Various Departments Such as Tumor Department
Personnels from Enterprises in Upstream, Midstream and Downstream Industrial Chain of Cell Therapy
Researchers from Universities and Institutes
Dear Mr./Ms.
You have registered successfully, the registration information and attention has been sent to the contact and the participants of the mailbox, please note that check. If not received, please contact the general meeting
